Falls Church, VA (PRWEB)
May 16, 2017
Brexit and Life Sciences Companies
**An FDAnews Webinar**
May 31, 2017 — 1:30 p.m. – 3:00 p.m. ET
When Britain exits the EU, what happens?
Will the EMA stay in London? What happens with the Unified Patient Court?
The Brexit is about to happen. Manufacturers need answers before that happens.
Get a look into the Brexit future. Mark the calendar for a standout webinar presentation on Wednesday, May 31 with a lawyer who specializes in the global drug and device business.
Michael Burke Esq., Partner, Arnall Golden Gregory LLP is his firm’s in-house expert on drugs and devices as well as a specialist in cross-border international trade. His particular focus, Ireland, is the one remaining English-speaking nation in a post-Brexit EU.
Mr. Burke counsels transnational drug and device clients on trade issues including anti-boycott regulations, export controls, economic sanctions and the Foreign Corrupt Practices Act, to mention just a few. In 90 intense minutes, he’ll answer the following questions and more:
How might Brexit affect my operation, both short- and long-term?
- Should manufacturers consider moving operations into or out of the U.K?
- What are the advantages and disadvantages of operating in Ireland?
- How will marketing authorization in both the EU and U.K. be affected?
Meet the Presenter:
Michael Burke Esq., Partner, Arnall Golden Gregory LLP
Washington lawyer Michael Burke has dual qualifications as a guide to the post-Brexit world: He is his firm’s in-house expert on drugs and devices; and a specialist in cross-border international trade. His particular focus,…